SBIR-STTR Award

An in vitro assay for toxic particulates
Award last edited on: 5/7/02

Sponsored Program
SBIR
Awarding Agency
NIH : NIEHS
Total Award Amount
$50,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
John W Harbell

Company Information

BioReliance Corporation (AKA: Microbiological Associates Inc)

14920 Broschart Road
Rockville, MD 20850
   (301) 738-1000
   info@bioreliance.com
   www.bioreliance.com
Location: Multiple
Congr. District: 08
County: Montgomery

Phase I

Contract Number: 1R43ES005152-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1989
Phase I Amount
$50,000
The purpose of this research is to establish a rapid, inexpensive, in vitro system for studying the cytotoxicity and genotoxicity of particulates potentially hazardous to the respiratory system. Short-term tests currently available to the research community were designed and optimized using soluble test materials and have been adapted to the study of particulates with limited phagocytic capacity of the target cells. The assay system to be developed will use a functional mouse macrophage cell line. This cell line, RAW264.7, is avidly phagocytic, can undergo a respiratory burst, and grows readily in culture. This latter feature will allow both cytotoxicity and genotoxicity endpoints to be measured. The Phase I goals are to: (1) establish the optimal conditions for a cytotoxicity assay, (2) validate the cytotoxicity assay with known toxic particulates, (3) establish the assay conditions for an HGPRT-based forward mutation assay, and (4) assay several known cases of mutagenic particulates.

Anticipated Results:
The commercial application of this research is a rapid, sensitive, relatively inexpensive in vitro assay for the cytotoxicity and mutagenicity of particulates.National Institute Of Environmental Health Sciences (NIEHS)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----